---
figid: PMC5824910__10.1177_1758834018757175-fig1
figlink: /pmc/articles/PMC5824910/figure/fig1-1758834018757175/
number: Figure 1
caption: 'G-alpha signaling pathway in uveal melanoma (adapted from Patel M et al.
  Clin Cancer Res 2011; 17(8): 2087–2100). G-protein coupled receptors (GPCR) signal
  through the heterotrimeric proteins, Gα and Gβγ. Mutations in GNAQ or GNA11 lead
  to constitutive activation of Gα and downstream stimulation of the mitogen-activated
  protein kinase (MAPK) pathway via phospholipase C (PLCβ) and protein kinase C (PKC).
  The phosphotidylinositol-3 kinase (PI3K)/Akt/mTOR and the Yes-activated protein
  (YAP) pathways are also activated. All three signaling pathways contribute to tumor
  growth and proliferation. Targeted therapy against various downstream effectors
  have had limited clinical efficacy. ORR - overall response rate; PFS - progression-free
  survival.'
pmcid: PMC5824910
papertitle: 'Treatment of uveal melanoma: where are we now?.'
reftext: Jessica Yang, et al. Ther Adv Med Oncol. 2018;10:1758834018757175.
pmc_ranked_result_index: '8884'
pathway_score: 0.9701616
filename: 10.1177_1758834018757175-fig1.jpg
figtitle: G-alpha signaling pathway in uveal melanoma
year: '2018'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5824910__10.1177_1758834018757175-fig1.html
  '@type': Dataset
  description: 'G-alpha signaling pathway in uveal melanoma (adapted from Patel M
    et al. Clin Cancer Res 2011; 17(8): 2087–2100). G-protein coupled receptors (GPCR)
    signal through the heterotrimeric proteins, Gα and Gβγ. Mutations in GNAQ or GNA11
    lead to constitutive activation of Gα and downstream stimulation of the mitogen-activated
    protein kinase (MAPK) pathway via phospholipase C (PLCβ) and protein kinase C
    (PKC). The phosphotidylinositol-3 kinase (PI3K)/Akt/mTOR and the Yes-activated
    protein (YAP) pathways are also activated. All three signaling pathways contribute
    to tumor growth and proliferation. Targeted therapy against various downstream
    effectors have had limited clinical efficacy. ORR - overall response rate; PFS
    - progression-free survival.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CB
  - PIK3CA
  - NMUR1
  - MAP2K1
  - MAP2K2
  - GNAQ
  - PIK3R6
  - PIK3R5
  - PIK3CD
  - PIK3R4
  - TRIO
  - PIK3R3
  - PRKD3
  - PIK3CG
  - RHOG
  - RAC1
  - RAC2
  - RAC3
  - MTOR
  - PRKCI
  - PRKCQ
  - RAF1
  - PRKCZ
  - PLCB1
  - YY1AP1
  - AMOT
  - MAPK1
  - MAPK3
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - ARAF
  - PLCB3
  - BRAF
  - RHOD
  - PLCB2
  - AKT3
  - PLCB4
  - PRKCA
  - PTEN
  - AKT1
  - AKT2
  - AEBO71
  - BYL719
  - Ga
  - GDP
  - Trametinib
  - Selumetinib
  - Cancer
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: GPCR
  symbol: GPC-R
  source: hgnc_alias_symbol
  hgnc_symbol: NMUR1
  entrez: '10316'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: GNAQ/11
  symbol: GNAQ
  source: hgnc_symbol
  hgnc_symbol: GNAQ
  entrez: '2776'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: Trio
  symbol: TRIO
  source: hgnc_symbol
  hgnc_symbol: TRIO
  entrez: '7204'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: Rac
  symbol: RAC
  source: bioentities_symbol
  hgnc_symbol: RHOG
  entrez: '391'
- word: Rac
  symbol: RAC
  source: bioentities_symbol
  hgnc_symbol: RAC1
  entrez: '5879'
- word: Rac
  symbol: RAC
  source: bioentities_symbol
  hgnc_symbol: RAC2
  entrez: '5880'
- word: Rac
  symbol: RAC
  source: bioentities_symbol
  hgnc_symbol: RAC3
  entrez: '5881'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: PLCB
  symbol: PLCB
  source: bioentities_symbol
  hgnc_symbol: PLCB1
  entrez: '23236'
- word: YAP
  symbol: YAP
  source: hgnc_alias_symbol
  hgnc_symbol: YY1AP1
  entrez: '55249'
- word: Amot
  symbol: AMOT
  source: hgnc_symbol
  hgnc_symbol: AMOT
  entrez: '154796'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PLCB
  symbol: PLCB
  source: bioentities_symbol
  hgnc_symbol: PLCB3
  entrez: '5331'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Rho
  symbol: Rho
  source: hgnc_alias_symbol
  hgnc_symbol: RHOD
  entrez: '29984'
- word: PLCB
  symbol: PLCB
  source: bioentities_symbol
  hgnc_symbol: PLCB2
  entrez: '5330'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PLCB
  symbol: PLCB
  source: bioentities_symbol
  hgnc_symbol: PLCB4
  entrez: '5332'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
chemicals:
- word: AEBO71
  source: MESH
  identifier: C030706
- word: BYL719
  source: MESH
  identifier: C585539
- word: Ga
  source: MESH
  identifier: C043055
- word: GDP
  source: MESH
  identifier: D006153
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Selumetinib
  source: MESH
  identifier: C517975
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
